Figure 3C illustrates that THRAP3 is predicted to be a high-risk factor in PAAD. PFI analysis indicates that ACC, LGG, LIHC, and LUSC patients with THRAP3 overexpression had worse PFI, while KIRC patients with low expression had better PFI (Figure 3D). This evidence concerns the gene THRAP3 and pancreatic adenocarcinoma.